Alumis Inc.

Its money currently comes entirely from one licensing and collaboration agreement rather than product sales: an upfront payment, payments tied to development progress and regulatory or commercial milestones, and a royalty on sales in one overseas territory once earned. The company has recorded losses rather than profit in the periods on file, consistent with a business still spending on development ahead of any broader product revenue.

Alumis currently spends ahead of any broad revenue, recording losses rather than profit in the years on file, and it shares this basic shape with a large group of peers built the same way. For companies built this way, growth typically does not scale smoothly with volume. It moves in large discrete steps tied to trial results, regulatory clearances and licensing deals such as the one already in place, rather than to incremental unit sales. This reflects CompanyGraph's own interpretation of how this kind of system tends to grow, not a measurement of Alumis's own trajectory.

Alumis depends on outside manufacturers for its drug substances rather than making them itself, drawing raw materials and manufacturing services from suppliers concentrated in a handful of overseas regions. It also depends on outside clinical-trial sites and research organizations to run its studies, on regulators to clear each development stage, on its scientific and management staff, on legal protection of its intellectual property, and on its licensing partner for the revenue it currently earns.

The one business relationship on record that currently depends on Alumis is its licensing partner, Kaken, which holds exclusive rights to develop and sell one of its drug candidates in a specific overseas market and which is also the source of all the revenue Alumis presently earns. Beyond that single partner, Alumis has no approved products on the market yet, so no broader named base of customers depends on it at this point.

CompanyGraph counts several dozen other companies operating the same fundamental kind of system, developing candidates through a regulated approval process before earning broad revenue, so this basic shape is a common one, not one specific to Alumis. In its own filings, Alumis attributes its edge to a proprietary data-analytics platform and biological insights used to select and design its drug candidates. CompanyGraph has not independently verified that this is harder for competitors to replicate than for others in the same position.

The one contractual relationship with disclosed terms, the licensing and collaboration agreement with Kaken, grants Kaken exclusive rights to one specific drug candidate in one national market, with payment obligations and an optional right that extend years into the future rather than resolving immediately. Because the license covers a particular compound that Alumis alone controls rather than a substitutable input, Kaken would need to start over with an entirely different, unproven candidate elsewhere in order to walk away from the arrangement.

Companies that operate this kind of system are structurally bound by the regulatory gate: nothing they develop can earn broad revenue until an approval process clears it, and that gate is CompanyGraph's starting assumption for what limits Alumis, not a measurement of Alumis itself. In its own filings, Alumis names a more immediate set of limits: how much financing it can raise, how many patients it can enroll in trials, the capacity of the outside manufacturers and suppliers it relies on, and its ability to recruit and keep management and scientific staff.

In its own risk disclosures, Alumis lists first its limited operating history, absence of any approved product and ongoing losses, difficulty enrolling and keeping patients in its clinical trials, and its need to raise substantial further financing to continue. It also discloses that all of its current revenue runs through a single licensing partner and that it depends heavily on the success of one specific drug candidate, so a setback to either would affect essentially all of its present income and a central part of its pipeline at the same time.

Alumis's development work is governed by medicine regulators in the United States and Europe, whose approval it needs before any candidate can be sold. It also carries pending legal disputes on record, including one tied to a prior merger and another over a milestone and royalty obligation from an earlier licensing deal, and it sources raw materials and manufacturing from a small number of overseas regions that expose it to tariffs, trade restrictions and import delays, along with unhedged foreign-currency costs from the overseas vendors it uses.